Physician profile
Deepika Bhargava
NPI 1841268992
$10,912.57
in general payments reported to CMS, 2019-2025
30 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $276 · 2021: $582 · 2022: $582 · 2023: $6,520 · 2024: $896 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,910.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $6,000.00 | 2023 | Brainsway Deep Tms |
| Teva Pharmaceuticals USA, INC. | $1,199.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $409.63 | 2019-2022 | |
| Tris Pharma INC | $391.41 | 2024-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $365.47 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.85 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $330.64 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $264.25 | 2023-2025 | Auvelity |
| Alkermes, INC. | $263.78 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $219.97 | 2021-2025 | Rexulti |
| Eisai INC. | $178.00 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $103.66 | 2019-2024 | Ingrezza |
| Neuronetics, INC. | $98.89 | 2019-2023 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $96.07 | 2024 | |
| Abbvie INC. | $95.78 | 2021-2025 | Vraylar |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $71.74 | 2019 | |
| Corium, LLC | $66.46 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $54.78 | 2022-2023 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $53.50 | 2024-2025 | Qelbree |
| Lundbeck LLC | $49.29 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $42.81 | 2024-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $31.90 | 2019-2022 | |
| Allergan, INC. | $28.54 | 2020 | |
| Janssen Biotech, INC. | $22.96 | 2023 | |
| Almatica Pharma LLC | $22.63 | 2024 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $21.43 | 2019 | |
| Indivior INC. | $20.86 | 2023 | Perseris |
| Merck Sharp & Dohme LLC | $19.26 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.48 | 2023 | Quviviq |
| Pear Therapeutics (US), INC. | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.